Supply Chain Intelligence

Bicara Therapeutics Inc. Supply Chain

BCAX supply chain intelligence for Bicara Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

BCAX ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
1Customers
2Debt Items
20Related Chains

Bicara Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
BIOCON BIOCON 90% Pursuant to the terms of the master service agreement, Biocon provided services related to research and development, clinical trials, regulatory interactions and manufacturing.
BIOCON-BIOLOGICS-LIMITED BIOCON-BIOLOGICS-LIMITED 90% Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to Bicara to be utilized in research and development and manufacturing as per purchase orde…
SYNGENE-INTERNATIONAL-LIMITED SYNGENE-INTERNATIONAL-LIMITED 90% Pursuant to the terms of the Syngene Agreements, Syngene manufactures and supplies specified quantities of products to Bicara to be used in research and development as per purchase orders executed fr…
IQVIA-RDS-INC IQVIA-RDS-INC 85% Pursuant to the terms of the agreement, as amended, IQVIA will provide the Company with certain global clinical-development related services and laboratory services under separately executed statemen…
PLRX Pliant Therapeutics, Inc. 72% Reciprocal relationship from PLRX graph: duct candidates and jeopardize our ability to commercialize our product candidates and generate revenue. 32 In addition, there are risks associated with large…

Bicara Therapeutics Inc. Customers

TickerNameConfidenceEvidence
PLRX Pliant Therapeutics, Inc. 72% Reciprocal relationship from PLRX graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from BCAX graph: Reciprocal relationship from PLRX g…

Bicara Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
BCAX-DEBT Debt stack $1.4M 90% Market cache reports total debt of $1.4M.
BCAX-DEBT-8093 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.

Bicara Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Bicara Therapeutics Inc..

Bicara Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
BCAX-OWNER-RA-CAPITAL-MANAGEMENT-L-P RA CAPITAL MANAGEMENT, L.P. 90% 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 149 tracked holders.

Bicara Therapeutics Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CSTE Caesarstone Ltd. 100.00 2
CLDX Celldex Therapeutics, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 1 ['receiving']
AUTL Autolus Therapeutics plc 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
BDRX Biodexa Pharmaceuticals Plc 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
DEO Diageo plc 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
View BCAX supply chain intel →

Explore the full interactive supply chain map for Bicara Therapeutics Inc..

Open BCAX supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map